NEW DRUG APPLICATION FILED FOR BTG'S OXYCODONE HCL/IBUPROFEN TECHNOLOGY

Main Menu | News By Date | News By Supplier | News By Category | About Us

NEW DRUG APPLICATION FILED FOR BTG'S OXYCODONE HCL/IBUPROFEN TECHNOLOGY
10 October 2006 - BTG

BTG, the global technology commercialisation company, announced today that Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, has submitted a New Drug Application with the U.S.

Food and Drug Administration to market oxycodone HCl/ibuprofen for the treatment of moderate and severe pain. Oxycodone HCl/ibuprofen, BTG’s licensed technology, is a patented combination of oxycodone, a powerful analgesic, and ibuprofen, one of the most widely used and trusted non-steroidal anti-inflammatory drugs.

Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories, stated: "The filing of this application, based on the technology licensed from BTG, represents an important opportunity for Forest Laboratories in the $2.5 billion analgesic market. Forest has successfully marketed several pain products and we believe that this new analgesic combination which contains an effective dose of oxycodone and the optimal dose of ibuprofen, may be particularly useful where other available analgesics and analgesic combinations do not provide adequate pain relief."

The oxycodone component, already used to great success in combination with aspirin, has proven effective in treating patients with moderate to severe pain. The new drug is a combination of oxycodone with a well-recognised anti-inflammatory, ibuprofen, which has the potential to be of great benefit to many patients in pain. The potential oxycodone/ibuprofen composition is licensed exclusively to Forest from BTG.

Dr Geoffrey Porges, Executive Vice President, Health, Medical and BioTechnologies at BTG, commented: "This combination is a potentially important addition to the range of new analgesic agents. We are delighted with the tremendous progress Forest Laboratories has made in reaching this milestone. This product reinforces the commercial success BTG has achieved recently with the launch of Campath."

http://www.btgplc.com

About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively.

More News:
  • For October 2006
  • From BTG
  • For Polymer OLED Devices